TCBP: TC BioPharm Ltd Price to Sales
The price-to-sales ratio dynamics of TC Biopharm (TCBP) highlight the value of patents in the allogeneic T-cell product sector, where 0.20 reflects the latest metric value. The development of innovative cancer treatment methods leverages management's oncology expertise, while active research into gamma-delta therapies and anticipated test results confirm the high scientific intensity of the company's processes.
%20Plc%3A%20Market%20Cap%20to%20Revenue&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_TCBP_-_TC-Biopharm_-_Market-Cap-to-Revenue "TC BioPharm Ltd - TCBP Market Cap to Sales Volume (period 04/28/2023 - 09/30/2024) | 👁️GURU.Markets👁️")
Analytical breakdowns for TC BioPharm (Holdings) PLC (TCBP)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- business debt structure and liquidity details:
- earnings and market ratios statistics:
TCBP - Net Profit|Expected Net Income TC Biopharm|TCBP - P/E Multiple|Forward P/E Multiple TC BioPharm (Holdings) Plc|TCBP - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation TC BioPharm Ltd|TCBP - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months TC BioPharm|TCBP - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months tcbiopharm.com|TCBP - Earnings growth in current year|Expected earnings per share growth for next year TC Biopharm
- issuer revenue and sales details:
General company analysis:TCBP, tcbiopharm.com
The price-to-sales ratio measures the premium the market is willing to pay per unit of revenue, allowing for an assessment of revenue generation efficiency relative to the business value. An analysis of the price-to-sales multiple for TC Biopharm (TCBP) reflects speculative investor expectations, as a future monopoly pricing power upon the approval of T-cell therapies could radically alter the company's fundamental value.
Competitors of TC Biopharm
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA: Market Cap to Revenue|Protagonist Corp - Market Cap to Sales Volume|IMVT: P/S Multiple|Market Cap to Revenue kiniksa.com|Market Cap to Revenue GRFS|ADPT: Market Capitalization-to-Revenue Ratio|P/S Multiple CLDX|Price-to-Revenue Ratio AUPH (Aurinia Corp)|P/S Multiple BCRX (BioCryst)|Price-to-Revenue Coefficient veratx.com (VERA)|DNTH - Price-to-Revenue Ratio|Price to Sales Pharvaris NV|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|Price-to-Sales Ratio TRML (Tourmaline)|PGEN (Precigen, Inc.) - P/S Multiple|PHAR: Market Capitalization-to-Revenue Ratio|P/S Multiple NKTR|P/S Multiple Upstream Bio, Inc. (UPB)|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Market Capitalization-to-Revenue Ratio IMNM|GOSS - Price-to-Revenue Ratio|kalvista.com (KALV) - Market Cap to Revenue|SEPN (Septerna) - Market Cap to Revenue|PVLA: Market Cap to Sales Volume|SVRA (Savara Corp) - P/S Multiple|Market Cap to Revenue Rigel Corp (RIGL)|P/S Multiple ANAB|Price-to-Revenue Ratio ATXS (astriatx.com)|Price-to-Revenue Ratio enGene ENGN|RAPT (RAPT Therapeutics Inc.) - Price-to-Sales Ratio|JBIO - Price-to-Revenue Ratio|Price-to-Sales Ratio ACRS|KYTX: P/S Multiple|tizianalifesciences.com - Market Capitalization-to-Revenue Ratio|CABA (Cabaletta Bio) - P/S Multiple|P/S Multiple Ventyx Biosciences Inc.|Price-to-Revenue Ratio Theratechnologies Inc (THTX)|AVTX (Avalo Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Eledon Pharmaceuticals ELDN|AGEN - Market Cap to Revenue|Climb Bio - P/S Multiple|ZURA - P/S Multiple|ATYR (aTyr) - Market Cap to Revenue|Adagene Inc. - Market Capitalization-to-Revenue Ratio|IMA (ImageneBio) - P/S Multiple|Shattuck Therapeutics (STTK) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Equillium, Inc. (EQ)|Market Cap to Revenue connectbiopharm.com CNTB|Price-to-Revenue Ratio Immunic IMUX|ATRA - Market Cap to Revenue|IFRX: Market Cap to Revenue|XFOR - P/S Multiple|adicetbio.com (ACET) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CELU|INMB (INmune Bio Corp) - P/S Multiple|Price to Sales Barinthus Biotherapeutics Corp BRNS|Market Cap to Revenue KZR (Kezar Life Sciences)|Market Cap to Sales Volume SABS|P/S Multiple AKTX (Akari Therapeutics Plc)|ENLV - Market Cap to Revenue|QTTB: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio GOVX (GeoVax Corp)|EDSA: P/S Multiple|IBIO (ibioinc.com) - Price-to-Revenue Ratio|CARM (Carisma Therapeutics Inc) - P/S Multiple|XTL Biopharmaceuticals Ltd (XTLB) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Bolt Biotherapeutics (BOLT)|HCWB - Price to Sales|Price-to-Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM (AIM ImmunoTech, Inc.) - Price-to-Sales Ratio|Aditxt Corp - P/S Multiple|Market Capitalization-to-Revenue Ratio GRI (GRI Bio Inc)|XRTX: P/S Multiple|Vyome Therapeutics (HIND) - P/S Multiple|Price-to-Revenue Ratio Revelation Biosciences|INDP: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|Market Cap to Revenue calcimedica.com CALI|Affimed N.V. - Market Cap to Revenue|Market Cap to Sales Volume ALLK (Allakos Inc)|HOOKIPA - P/S Multiple|IGM Biosciences, Inc. (IGMS) - Market Cap to Revenue|ITOS: P/S Multiple|OCEA (Ocean Biomedical Inc) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Third Harmonic Bio, Inc
